Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs CCB for salt-sensitive hypertension
ChiCTR2000038105Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in hypertension (HTN) (3 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: 24-hour ambulatory blood pressure and Office blood pressure (OBPM). Started Oct 2020; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2000038105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038105.